| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,916.4 | 24,587.9 | 21,439.1 | 18,972.2 | 17,460 |
Other Operating Income | 94.7 | 81.8 | 106.1 | 75.3 | 57 |
Other Income | 909 | 1,092.5 | 554.7 | 339.4 | 676.7 |
Total Income | 28,920.1 | 25,762.2 | 22,099.9 | 19,386.9 | 18,193.7 |
Total Expenditure | 20,078 | 18,320.7 | 17,777.5 | 15,177.6 | 15,046.6 |
PBIDT | 8,842.1 | 7,441.5 | 4,322.4 | 4,209.3 | 3,147.1 |
Interest | 171.1 | 142.8 | 95.8 | 97 | 98.3 |
PBDT | 8,671 | 7,298.7 | 4,226.6 | 4,112.3 | 3,048.8 |
Depreciation | 1,470 | 1,250.2 | 1,165.2 | 1,228.8 | 1,163.1 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,945.9 | 814.4 | 1,101.3 | 817.2 | 661.6 |
Deferred Tax | -322.8 | 726.8 | -222.4 | 114.7 | -801.9 |
Reported Profit After Tax | 5,577.9 | 4,507.3 | 2,182.5 | 1,951.6 | 2,026 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 5,577.9 | 4,507.3 | 2,182.5 | 1,951.6 | 2,026 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 5,577.9 | 4,507.3 | 2,182.5 | 1,951.6 | 2,026 |
EPS (Unit Curr.) | 335.22 | 271.47 | 131.57 | 117.67 | 122.22 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 800 | 800 | 600 | 500 | 500 |
Equity | 83.4 | 83.3 | 83.2 | 83.2 | 83.1 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 31.67 | 30.26 | 20.16 | 22.18 | 18.02 |
PBDTM(%) | 31.06 | 29.68 | 19.71 | 21.67 | 17.46 |
PATM(%) | 19.98 | 18.33 | 10.17 | 10.28 | 11.6 |
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Here are some of the stocks that may see significant price movement today: KPI Green, Tata Power, UltraTech Cement, etc.
Dr Reddy's Laboratories third quarter net profit rose 2.5% year-on-year (YoY) to ₹1,413.3 crore.
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
